Effect of Genzyme Corporation (GENZ)'s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies
3/28/2013 9:15:49 AM
MISSISSAUGA, ON, March 28, 2013 /CNW/ - Genzyme, a Sanofi Company announced interim results from the first year of the extension study of LEMTRADA™ (alemtuzumab), being developed for the treatment for multiple sclerosis (MS). The data were presented March 21 at the American Academy of Neurology meeting in San Diego, California.
comments powered by